

## CDR PUBLICATIONS IN WHICH COGNITION ENHANCEMENT HAS BEEN IDENTIFIED

### Healthy Volunteers

- Birch B and Curran HV (1990). The differential effects of flumazenil on the psychomotor and amnesic actions of midazolam. Journal of Psychopharmacology 4: 29-34.
- Bosworth J, Jensen NO, Oliver S, Wesnes KA (1999) First cognitive effects of NS2359, a noradrenaline, dopamine & serotonin reuptake inhibitor, in volunteers [Abstract]. Journal of Psychopharmacology 13 (Suppl. A): A26.
- Bradford E, Nield H, Wesnes K. (2006) An internet survey of the cognitive differences between self-reported users and non-users of a standardised combination of ginseng, vitamins and minerals. Journal of Psychopharmacology 20 (5): A30
- Coley DA, Greeves R, Saxby BK (2007) The Effect of Low Ventilation Rates on the Cognitive Function of a Primary School Class. International Journal of Ventilation 6: 1473-3315.
- Dunbar G, Boeijinga PH, Demazieres A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R. (2007). Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology 191: 919-929.
- Dunbar G, Kuchibhatla R (2006). Cognitive enhancement in man with ispronicline, a nicotinic partial agonist. Journal of Molecular Neuroscience 30: 169-171.
- Ebert U, Oertel R, Wesnes K, Kirch W (1998). Effects of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance. Human Psychopharmacology 13: 199-210.
- Edgar C, Wesnes K, Zangara A (2004) The effects of Donepezil in healthy elderly volunteers on a scopolamine-challenge model of cognition [Abstract]. Journal of Psychopharmacology 18 (Suppl): A51
- Edwards J, Wesnes K, Warburton DM, Gale A (1985). Evidence of more rapid stimulus evaluation following cigarette smoking. Addictive Behaviours 10: 113-126.
- Ford CE, Scholey AB, Ayre G, Wesnes K (2002). The effect of glucose administration and the emotional content of words on heart rate and memory. Journal of Psychopharmacology 16: 241-244.

- Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB. (2008). The effects of L-theanine, caffeine and their combination on cognition and mood. Biol Psychol. 77(2):113-22.
- Haskell CF, Kennedy DO, Wesnes KA, Milne AL, Scholey AB. (2007). A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans. Journal of Psychopharmacology 21: 65-70.
- Haskell CF, Kennedy DO, Wesnes KW, Scholey AB. (2005) Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology 179: 813-825.
- Ingwersen J, Defeyter MA, Kennedy DO, Wesnes KA, Scholey AB. (2007) A low glycaemic index breakfast cereal preferentially prevents children's cognitive performance from declining throughout the morning. Appetite 49: 240-244.
- Jones MEE, Parrott A, Wesnes K. (1998). The effects of caffeinated and decaffeinated beverages on cognitive performance, heart rate and mood in shift workers [Abstract]. Journal of Psychopharmacology 12: Supplement A, A42.
- Jones RW, Wesnes KA, Kirby J (1991). Effects of NMDA modulation in scopolamine dementia. Annals of the New York Academy of Sciences 640: 241-244.
- Jones S, Jensen NO, Oliver S, Wesnes KA (1999) First in man cognitive effects of NS2330, a novel monoamine reuptake inhibitor, in volunteers [Abstract]. Journal of Psychopharmacology 13 (Suppl. A): A26.
- Kennedy DO, Haskell CF, Mauri PL, Scholey AB (2007) Acute cognitive effects of standardised Ginkgo complexed with phosphatidylserine. Human Psychopharmacology 22: 199-210.
- Kennedy DO, Haskell CF, Wesnes KA, Scholey AB (2004). Improved cognitive performance following acute administration of Guarana (*Paullinia cupana*) containing low levels of caffeine: comparison and interaction with *Panax Ginseng*. Physiology, Biochemistry and Behavior 79: 401-11
- Kennedy DO, Jackson P, Haskell CF, Scholey AB (2007). Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers. Human Psychopharmacology 22: 559-556.
- Kennedy DO, Scholey AB, Tildesley NTJ, Perry EK, Wesnes KA (2002). Modulation of mood and cognitive performance following acute administration of melissa officinalis (lemon balm). Pharmacology, Biochemistry and Behaviour 72: 953-964.
- Kennedy DO, Scholey AB, Wesnes K (2002). Modulation of cognition and mood following administration of single doses of ginkgo biloba, ginseng and a ginkgo/ginseng combination to healthy young adults. Physiology & Behaviour 75:1-13.

- Kennedy DO, Scholey AB, Wesnes KA (2000). The dose-dependent cognitive effects of acute administration of ginkgo biloba to healthy young volunteers. Psychopharmacology 151: 416-423.
- Kennedy DO, Scholey AB, Wesnes KA (2001). Dose dependent changes in cognitive performance and mood following acute administration of ginseng to healthy young volunteers. Nutritional Neuroscience 4: 295-310.
- Kennedy DO, Scholey AB, Wesnes KA (2001). Differential, dose dependent changes in cognitive performance following acute administration of a ginkgo biloba /panax ginseng combination to healthy young volunteers. Nutritional Neuroscience 4: 399-412.
- Kennedy DO, Wake G, Savelev S, Tildesley NTJ, Perry EK, Wesnes KA, Scholey AB (2003). Modulation of Mood and Cognitive Performance Following Acute Administration of Single Doses of Melissa Officinalis (Lemon Balm) with Human CNS Nicotinic and Muscarinic Receptor-Binding Properties. Neuropsychopharmacology 28: 1871–1881.
- Kitagawa H, Takenouchi T, Azuma R, Wesnes K, Kramer WG, Clody DE, Burnett A (2003). Safety, pharmacokinetics and effects on cognitive function of multiple doses of GTS-21 in healthy male volunteers. Neuropsychopharmacology 28: 912–955.
- Labadorf C, Manktelow TC, Labadorf S, Edgar CJ, Wesnes K, Petrini O (2004) The global cognitive effects of ginseng taken by healthy volunteers over a 21 day period [Abstract]. Journal of Psychopharmacology 18 (Suppl): A44.
- Maher B, Stough C, Shelmerdine A, Wesnes K, Nathan P (2002). The acute effects of combined administration of *Ginkgo biloba* and *Bacopa monniera* on cognitive functions in humans. Human Psychopharmacology 17: 163-164.
- Marshall I, Wesnes KA, Pincock C (2003) Comparative profiles of caffeine and nicotine on attention [Abstract]. Journal of Psychopharmacology 17 (Suppl.): A64
- Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin J-L, Guez D, Boyer P-A (2002). S17092: A Prolyl Endopeptidase Inhibitor as a Potential Therapeutic Drug for Memory Impairment: Preclinical and Clinical Studies. CNS drug Reviews 8: 31-52.
- Moss M, Cook J, Wesnes K, Duckett P (2003). Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. International Journal of Neuroscience 113:15-38.
- Moss M, Hewitt S, Moss L and Wesnes K (2008). Modulation of Cognitive Performance and Mood by Aromas of Peppermint and Ylang-Ylang. International Journal of Neuroscience 118: 59-77.
- Moss MC, Scholey AB, Neave N, Stubbs P, Wesnes KA. (1998). Oxygen administration and cognitive performance in the elderly: a case of

- selective enhancement [Abstract]. Journal of Psychopharmacology 12: Supplement A, A41.
- Moss MC, Scholey AB, Wesnes KA (1998). Oxygen administration selectively enhances cognitive performance in healthy young adults: A placebo-controlled double-blind crossover study. Psychopharmacology 138: 27-33.
- Nathan PJ, Ricketts E, Wesnes K, Mrazek GW, Stough C (2002). The acute nootropic effects of ginkgo biloba in healthy older human subjects: a preliminary investigation. Human Psychopharmacology 17: 45-49.
- Neave N, Scholey AB, Emmett JR, Moss M, Kennedy DO, Wesnes KA (2001). Water ingestion improves subjective alertness, but has no effect on cognitive performance in dehydrated healthy young volunteers. Appetite 37: 255-256.
- Parrott A, Garnham N, Wesnes K, Pincock C (1996). Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours. Human Psychopharmacology 11: 391-400.
- Parrott AC, Craig D (1992). Cigarette smoking and nicotine gum (0mg, 2mg, 4mg): effects upon different aspects of visual attention. Neuropsychobiology 25: 34-43.
- Parrott AC, Winder G. (1989). Nicotine Chewing Gum (2 mg, 4 mg) and cigarette smoking: comparative effects upon vigilance and heart rate. Psychopharmacology 97: 257-261.
- Preece AW, Iwi G, Davies-Smith A, Wesnes K, Butler S, Lim E, Valey A (1999). Effect of a 915-MHz simulated mobile phone signal on cognitive function in man. International Journal of Radiation Biology 75: 447-456.
- Rapeport WG, Forster P, McEwen J, Wesnes K. (1995). The evaluation of candoxatril in the scopolamine model of dementia [Abstract]. European Journal of Clinical Investigation 25, Suppl. 2: A64.
- Ryan J, Croft K, Mori T, Wesnes K, Spong J, Stough C (2008). An examination of the effects of the antioxidant Pycnogenol® on cognitive performance, serum lipid profile, Endocrinological and oxidative stress biomarkers in an elderly population. Journal of Psychopharmacology, in press
- Scholey A, Tildesley N, Ballard C, Wesnes KA, Tasker A, Perry EK, Kennedy DO (2008). An extract of *Salvia* (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology DOI 10.1007/s00213-008-1101-3.
- Scholey AB, Kennedy DO (2004). Cognitive and physiological effects of an "energy drink": an evaluation of the whole drink and of glucose, caffeine and herbal flavouring fractions. Psychopharmacology 176: 320-330.
- Scholey AB, Moss MC, Neave N, Wesnes K (1999). Cognitive performance, hyperoxia and heart rate following oxygen administration in healthy young adults. Physiology and Behaviour 67: 783-789.

- Scholey AB, Moss MC, Wesnes KA (1998). Oxygen and cognitive performance: the temporal relationship between hyperoxia and enhanced memory. Psychopharmacology 140: 123-126.
- Scholey AB, Reily C, Wesnes KA. (1999) Effects of nicotine administered via an inhaler on cognitive performance in smokers and never smokers [Abstract]. Journal of Psychopharmacology 13 (Suppl. A): A25
- Siegfried KR (1993). Pharmacodynamic and early clinical studies with velnacrine. Acta Neurologica Scandinavica. 149: 26-28.
- Silber B Y, Croft R J, Papafotiou K and Stough C (2006). The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology 187: 154-69
- Stough C, Downey LA, Lloyd J, Silber B, Redman S, Hutchison C, Wesnes K, Mathan P (2008) Examining the nootropic effects of Bacopa Monneria on Human Cognitive Functioning: 90 day , double-blind, placebo-controlled randomized trial. Phytotherapy Research 22: In press
- Súnram-Lea SI, Birchall RJ, Wesnes KA, Petrini O (2004). The effect of acute administration of 400MG of *Panax Ginseng* on cognitive performance and mood in healthy young volunteers. Current topics in Nutraceutical Research 3: 251-254.
- Tildesley NTJ, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, Scholey AB (2003). *Salvia Lavandulaefolia* (Spanish sage) enhances memory in healthy young volunteers. Pharmacology, biochemistry and behaviour 75: 669-674.
- Tildesley NTJ, Kennedy DO, Perry EK, Ballard CG, Wesnes KA, Scholey AB (2005). Positive modulation of mood and cognitive performance following administration of acute doses of *Salvia Lavandulaefolia* essential oil to healthy young volunteers. Physiology & Behavior 83 : 699-709.
- Wesnes K (1987). Nicotine increases mental efficiency, but how? In: Martin WR, Van Loon GR, Iwamoto ET, Davis DL (Eds.) Tobacco Smoke and Nicotine: A Neurobiological Approach. New York: Plenum, pp.63-81.
- Wesnes K, Anand R, Lorscheid T (1990). Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of ageing and dementia. Acta Psychiatrica Scandinavia 360: 71-72.
- Wesnes K, Anand R, Simpson PM, Christmas L (1990). The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. Journal of Psychopharmacology 4: 219-232.
- Wesnes K, Faleni RA, Hefting NR, Hoogsteen G, Houben JJG, Jenkins E, Jonkman JHJ, Leonard J, Petrini O, Van Lier JJ (1997). The cognitive, subjective and physical effects of a ginkgo biloba/ panax ginseng combination in healthy volunteers with neurasthenic complaints. Psychopharmacology Bulletin 33: 677-683.

- Wesnes K, Ferguson J, Petrini O (2004) The memory enhancing effects of ginkgo biloba in healthy middle-aged volunteers [Abstract]. International Journal of Neuropsychopharmacology 7 (Suppl): 271
- Wesnes K, Jones RW, Kirby J (1991). The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia. British Journal of Clinical Pharmacology 31: 577-578.
- Wesnes K, Luthringer R, Ambrosetti C, Edgar, Petrini O (2003). The effects of a combination of panax ginseng, vitamins and minerals on mental performance, mood and physical fatigue in nurses working night shifts: A double blind, placebo-controlled trial. Current Topics in Nutraceutical Research 1: 169-174.
- Wesnes K, Neuman E, de Wilde HJG, Malbezin M, Castagné I, Crijns HJMJ, Jonkman JHG, Guez D. (1994). Pharmacodynamic effects of a repeated oral administration of 4 dose levels of S12024-2 in 36 elderly volunteers [Abstract]. Neurobiology of Aging 15: S100.
- Wesnes K, Parrott A (1992). Smoking, nicotine and human performance. In Smith A, Jones D (Eds.) Handbook of Human Performance: Volume 2. London: Academic Press, pp. 127-167.
- Wesnes K, Pincock C, Richardson D, Helm G, Hails S (2003). Breakfast reduces declines in attention and memory over the morning in school children. Appetite 41: 329-331.
- Wesnes K, Revell A (1984). The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 84: 5-11.
- Wesnes K, Simpson P, Christmas L, Anand R and McClelland GR (1989). The effects of moclobemide on cognition. Journal of Neural Transmission 29: 91-102.
- Wesnes K, Simpson PM, Christmas L (1988). Puff by puff profiles of performance, mood and acceptability in low and non-low tar smokers. In: Rand MJ, Thurau K (Eds.) The Pharmacology of Nicotine. Oxford: IRL Press, pp. 406-408.
- Wesnes K, Simpson PM, Christmas L, Anand R, McClelland GR (1989). The effects of moclobemide on cognition. Journal of Neural Transmission 28: 91-102.
- Wesnes K, Simpson PM, Christmas L, McClelland GR, Joiner IM (1989). Acute cognitive effects of moclobemide and trazodone alone and in combination with alcohol in the elderly. British Journal of Clinical Pharmacology 27: 647-648.
- Wesnes K, Simpson PM, Jansson B, Grahnén A, Weimann HJ, Küppers H (1997). Moxonidine and cognitive function: Interactions with moclobemide and lorazepam. European Journal of Clinical Pharmacology 52: 351-358.

- Wesnes K, Simpson PM, Kidd A (1987). The use of a scopolamine model to study the nootropic effects of tenilsetam (CAS 997) in man. Medical Science Research 15: 1063-1064.
- Wesnes K, Simpson PM, White L, Pinker S, Jertz G, Murphy M, Siegfried K (1991). Cholinesterase inhibition in the scopolamine model of dementia. Annals of the New York Academy of Sciences 640: 268-271.
- Wesnes K, Strobel W. (1996). Flesinoxan improves cognition in the elderly [Abstract]. European Neuropsychopharmacology 6 Suppl 3: 186.
- Wesnes K, Warburton DM (1983). Effects of smoking on rapid information processing performance. Neuropsychobiology 9: 223-229.
- Wesnes K, Warburton DM (1983). Smoking, nicotine and human performance. Pharmacology and Therapeutics 21: 189-208.
- Wesnes K, Warburton DM (1984). Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82: 147-150.
- Wesnes K, Warburton DM (1984). The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology 82: 338-342.
- Wesnes K, Warburton DM, Matz B (1983). Effects of nicotine on stimulus sensitivity and response bias in a visual vigilance task. Neuropsychobiology 9: 41-44.
- Wesnes KA, Garratt C, Wickens M, Gudgeon A, Oliver S (2000). Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. British Journal of Clinical Pharmacology 49: 110-117.
- Wesnes KA, Macher J-P (2004) Modafinil reverses the marked attentional deficits produced by acute sleep deprivation in healthy volunteers [Abstract]. Journal of Psychopharmacology 18 (Suppl): A48
- Wesnes KA, Ramezani E, Oliver S. (1997). FK960 antagonises the memory impairments produced by scopolamine in healthy volunteers [Abstract]. Journal of Psychopharmacology 11 Suppl.: A57.
- Wesnes KA, Simpson PM, Wallnöfer A, Dingemans J, McClelland G, Malek N. (1994) Cognitive enhancement with physostigmine in young volunteers [Abstract]. Journal of Psychopharmacology 8 (Suppl): A19.
- Wesnes KA, Ward T, McGinty A, Petrini O (2000). The memory enhancing effects of a ginkgo biloba/ panax ginseng combination in healthy middle aged volunteers. Psychopharmacology 152: 353-361.
- Wilkinson L, Scholey A, Wesnes K (2002). Chewing gum selectively improves aspects of memory in healthy volunteers. Appetite 38: 1-2.

Wills K, Jensen NO, Oliver S, Wesnes KA (1999) Cognitive effects of NS2330, a novel monoamine reuptake inhibitor, in volunteers [Abstract]. Journal of Psychopharmacology 13 (Suppl. A): A27.

Zangara A (2003). The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's Disease. Pharmacology, Biochemistry and Behaviour 75: 675-686.

## **Patient Populations**

Allain H, Neuman E, Malbezin M, Salzman V, Guez D, Wesnes K, Gandon JM (1997). Bridging study of S12024 in 53 in-patients with Alzheimer's disease. Journal of the American Geriatrics Society 45: 125-126.

Blacker CVR, Greenwood D, Wesnes K, Wilson R, Woodward C, Howe I, Ali T (2004). Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome: a randomised controlled trial. Journal of the American Medical Association 292: 1195-1204.

Bullock R, Lane R (2007) Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Current Alzheimer's Research 4(3): 277-293.

Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement Disorders: 21: 1899-1907.

Dunbar G C, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M and Wamsley J (2007). Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). Journal of Psychopharmacology 21: 171-178.

Emre M, Aarsland D, Albanese A, et al. (2004). Rivastigmine for Dementia Associated with Parkinson's Disease. New England Journal of Medicine 351: 2509-18.

Fearn S, Hutchinson S, Riding G, Hill-Wilson G, Wesnes K, McCollum C (2003). Carotid Endarterectomy Improves Cognitive Function In-Patients with Exhausted Cerebrovascular Reserve. European Journal of Vascular and Endovascular Surgery 26: 529-536.

Ferguson J, Wesnes K, Schwartz G (2003). Reboxetine versus paroxetine versus placebo: Effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology 18: 1-6.

Galvin J, Cornblatt B, Newhouse P, Ancoli-Israel S, Wesnes K, Williamson D, Zhu Y, Sorra K, Amatniek J (2008). Effects of Galantamine on Measures of Attention: Results From two Clinical Trials in Alzheimer's Disease



- Patients With Comparisons to Donepezil. Alzheimer's Disease and Related Disorders 22: 30-38.
- Girdler NM, Fairbrother KJ, Lyne JP, Neave N, Scholey A, Hargaden N, Wesnes KA, Engler J, Rotherham NA (2002). A randomised crossover trial of post-operative cognitive and psychomotor recovery from benzodiazepine sedation: Effects of reversal with flumazenil over a prolonged recovery period. British Dental Journal 192: 335-339.
- Girdler NM, Lyne JP, Wallace R, Neave N, Scholey A, Wesnes KA, Herman C (2002). A randomised, controlled trial of cognitive and psychomotor recovery from midazolam sedation following reversal with oral flumazenil. Anaesthesia 57: 868-876.
- Goa KL, Fitton A. (1994). Velnacrine in Alzheimer's Disease: An Initial Appraisal of its Clinical Potential. CNS Drugs 1: 232-240.
- Harsh J R, Hayduk R, Rosenberg R, Wesnes K A, Walsh J K, Arora S, Niebler G E and Roth T (2006). The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Current Medical Research Opinion 22: 761-74.
- Hearing S, Wesnes K, Bowman C (1999). Beta-blockers and cognitive function in elderly hypertensive patients: Withdrawal and consequences of ACE inhibitor substitution. International Journal of Geriatric Psychopharmacology 2: 13-17.
- Hirshkowitz M, Black JE, Wesnes K, Niebler G, Arora S & Roth T (2006). Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respiratory Medicine 101: 616-627.
- Liberman JN, Stewart WF, Wesnes K, Troncoso J (2002). Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. Neurology: 58:1038-1044.
- McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000). Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. The Lancet 356: 2031-2036.
- McKeith IG, Wesnes KA, Perry E, Ferrara, R. (2004). Hallucinations Predict Attentional Improvements with Rivastigmine in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders 18: 94-100.
- McNamara (2002). Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care. Palliative Medicine 16: 425-434.
- Mohr E, Knott V, Sampson M, Wesnes K, Herting R, Mendis T (1995). Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. Clinical Neuropsychopharmacology 18: 28-38.
- Molloy S, Rowan E N, O'Brien J T, McKeith I G, Wesnes K and Burn D J (2006). The effect of levodopa on cognitive function in Parkinson's disease with and

- without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77: 1323-1328
- Morgan P T, Pace-Schott E F, Sahul Z H, Coric V, Stickgold R and Malison R T (2006). Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: Evidence for occult insomnia. Drug Alcohol Depend 82: 238-49.
- Pace-Schott EF, Stickgold R, Muzur A, Wigren PE, Ward AS, Hart CL, Walker M, Edgar C, Hobson JA (2005). Cognitive performance by humans during a smoked cocaine binge-abstinence cycle. Am J Drug Alcohol Abuse 31: 571-91
- Rai, G.S., Shovlin, C. & Wesnes, K. (1991). A double-blind, placebo controlled study of Gingko biloba extract ('Tanakan') in elderly out-patients with mild to moderate memory impairment. Curr. Med. Res. Opin. 12: 350-355.
- Roth T, White D, Schmidt-Nowara W, Wesnes KA, Niebler G, Arora S, Black J (2006) Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week multicentre, double-blind, randomised, placebo-controlled study in nCPAP-adherent adults. Clinical Therapeutics 28: 689-706
- Rowan E, McKeith IG, Saxby BK, Newby, Daniel S, Sanders J, Wesnes KA (2007). Effects of Donepezil on Central Processing Speed and Attentional measures in Parkinson's disease with Dementia and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders 23: 161–167.
- Kohli S, Fisher SG, Tra Y, Adams MA, Mapstone MM, Wesnes KA, Jean-Pierre P, Roscoe JA, Morrow GR (2009). The Effect of Modafinil on Cognitive Function in Breast Cancer Survivors. Cancer in press
- Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA (2008) Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial. Neurology 70:1858-1866.
- Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C (2004) Short Term Transdermal Estradiol Therapy, Cognition and Depressive symptoms in Healthy Older Women. A Randomised Placebo Controlled Pilot Cross-over Study. Psychoneuroendocrinology 30: 309-315
- Scholey A, Mackay I, McCue P, Moss M, Wesnes KA. (1999) Oxygen administration reverses cognitive deficits associated with Chronic Fatigue Syndrome [Abstract]. Proceedings of the British Psychological Society 7: 110.
- Siegfried K (1991). First clinical impressions with an ACTH analogue (HOE 427) in the treatment of Alzheimer's disease. Annals of the New York Academy of Sciences 640: 260-283.
- Siegfried KR (1993). The pharmacodynamics of velnacrine: Results and conclusions from clinical studies in healthy subjects and patients with

- Alzheimer's disease. In: Wilcock GK (Ed.) *The Management of Alzheimer's Disease*. Wrightson Biomedical Publishing, 189-201.
- Tekin S, Lane R (2006) Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study. *Progress in Neurotherapeutics and Neuropsychopharmacology* 1: 1–13.
- Tesch H, Liberati IM, et al. (2006). Assessment of the cognitive effects of once weekly epoetin alfa in anemic patients with hematologic malignancies receiving chemotherapy: results of the EPOLYM trial [Abstract]. *The Hematology Journal* 91 (suppl 1): 8-9.
- Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes K, Hammond G, Schwalen S (2005) Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. *Curr Med Res Opin* 21: 1423-1429.
- Wesnes K, Niebler G, Arora S (2005). The cognitive effects of armodafinil in patients with excessive sleepiness associated with OSAHS, narcolepsy, and shift work sleep disorder [Abstract]. *European Neuropsychopharmacology* 15 Supplement 3: S652.
- Wesnes K, Preskorn SH, Friesen S, Edgar CJ, Mikkelsen BO (2002) NS2330 enhances cognitive function in elderly volunteers with possible Alzheimers Disease [Abstract]. *Journal of Psychopharmacology* 16 (Suppl.): A29
- Wesnes K, Scott M, Boyle M, Surmon D, Wilcock G (1993) Use of the cognitive drug research computerised assessment system to assess the efficacy of THA and galantamine in Alzheimers Disease [Abstract]. *Psychopharmacology Bulletin* 30: 139
- Wesnes K, Scott M, Morrison S, Greenwood D, Russell-Duff K, Wilcock GK. (1998). The effects of galanthamine on attention in Alzheimer's disease [Abstract]. *Journal of Psychopharmacology* 12: Supplement A, A64.
- Wesnes K, Simmons D, Rook M, Simpson PM (1987). A double blind placebo controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. *Human Psychopharmacology* 2: 159-169.
- Wesnes KA (2007). Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. *Drugs of Today* 43: 349-359.
- Wesnes KA, McKeith IG, Edgar C, Ferrara R, Emre M, Lane R. (2005). Benefits of rivastigmine on attention in dementia associated with Parkinson disease. *Neurology* 65: 1654-1656.
- Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R (2002). Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. *Dementia and Geriatric Cognitive Disorders* 13: 183-192.

- Wesnes KA, Simpson PM, White L (1994). The cognitive effects of moclobemide and nortriptyline in elderly depressed patients [Abstract]. Journal of Psychopharmacology 8 : A20.
- Wesnes KA, Snorrason E, Valsson A, Bragee B, Greenwood D (2001). The cognitive effects of galanthamine in patients suffering from fibromyalgia [Abstract]. Journal of Psychopharmacology 15 (Suppl.): A58.
- Wesnes KA, Edgar C, Wroe SJ, Dean ADP (2009). Comparative Cognitive and Psychological Profiles of Remacemide and Carbamazepine and Validation of Measures: Data from the SEReNE Trial. Epilepsy & Behavior in press
- Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA (2006) ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study. Biological Psychiatry 59: 1065–1070.